Ophthalmic Business News

In recent decades, ophthalmology has been a leader in exploring cutting-edge technologies for combating blinding diseases, and innovative gene-based strategies have shown promising results.

EyeBio has completed a round of Series A funding, totaling $65 million, according to a press release.

Ocugen will offer 15,973,420 shares of its common stock for gross proceeds of about $53.5 million, according to a press release.

This must be what it was like for political columnists during the Trump years: an endless, ever-flowing font of material to work with.

Alcon reported $2.1 billion in worldwide sales for the fourth quarter of 2021, according to a press release, representing an increase of 11% on a reported basis and 13% on a constant currency basis compared with the fourth quarter of 2020.

One important success factor for physicians when it comes to investing is understanding how they are unlike most U.S. retail investors. Physicians have a level of education, income and, typically, net worth that far exceed those of most investors in our country. It is also important to recognize all investors, regardless of education or experience, are influenced by the media. The combination of these factors can create added challenges for physicians when deciding how to allocate their assets.

Glaukos is making executive leadership changes, including a new president and chief operating officer, effective April 1, according to a press release.

In this episode, Nicole Fram, MD, MPH, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss taking over as managing partner for Advanced Vision Care and Samuel Masket, MD, and shares her take on new products and technologies in eye care.

In this episode, David W. Parke II, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss stepping down as the AAO CEO, the highlights of what he accomplished during this time, and thoughts on the future of ophthalmology.

Tarsus Pharmaceuticals has completed enrollment in the second pivotal phase 3 trial investigating TP-03 for the treatment of Demodex blepharitis and secured a $175 million credit facility, according to a press release.